WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology-focused therapeutics company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. Jayson Rieger, PhD, MBA, President and CEO of Verrica, is set to join a fireside chat on Tuesday, April 8, 2025, at 1:30 PM ET. The virtual event will include a live webcast for participants and will be available for replay on Verrica’s website for 90 days after the presentation.
Advancing Dermatology Treatments
Verrica Pharmaceuticals specializes in developing treatments for serious skin conditions requiring medical intervention. Its flagship product, YCANTH® (VP-102), is the first and only FDA-approved cantharidin-based therapy for molluscum contagiosum, a highly contagious viral skin condition that affects approximately six million people in the U.S., primarily children. The product, approved for patients aged two and older, represents a significant advancement in dermatology therapeutics.
YCANTH® is also being investigated as a treatment for common warts, which remain one of the largest areas of unmet need in the field of medical dermatology. Beyond YCANTH®, Verrica is making strides in oncology. The company has a global licensing agreement with Lytix Biopharma AS to develop and commercialize VP-315, an investigational therapy targeting non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma.
Speaking about the company’s efforts, Jayson Rieger emphasized Verrica’s commitment to innovation in dermatology. “Our FDA-approved product YCANTH® has already made significant headway for patients with molluscum contagiosum, and our broader pipeline reflects our dedication to addressing key unmet needs in medical dermatology,” said Rieger.
Engagement in the Healthcare Community
The Needham Virtual Healthcare Conference is a prominent platform for emerging biotech and pharmaceutical companies to showcase their advancements. Verrica’s presence further establishes its standing as a leader in dermatology therapeutics and its commitment to driving innovation in treatments for skin diseases.
By participating in events like this, Verrica stays engaged with the healthcare investment community while sharing updates on its growing dermatology pipeline and addressing patient needs. The company’s progress reflects its strategic focus on delivering impactful solutions for skin conditions and strengthening its position in the dermatology market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.